In the case of prostate cancer theranostics, one could initially assume that the advent of radiolabeled theranostic PSMA-inhibitors in the clinic has imposed a serious challenge on the application of GRPR-antagonist radioligands [13]. The gene discussed is GRPR; the disease is prostate carcinoma.